Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition - Mallaroni P; Mason NL; Reckweg JT; Paci R; Ritscher S; Toennes SW; Theunissen EL; Kuypers KP; Ramaekers JG. (bioRxiv, 2023)

Psychedelics for the Neuropsychiatric Symptoms of Alzheimer's disease - Ashish Sarangi; Omotola Akinkunmi (American Journal of Geriatric Psychiatry, 2023)

Considerations in assessing the abuse potential of psychedelics during drug development. - Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D (Neuropharmacology, 2023)

Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. - Shnayder S; Ameli R; Sinaii N; Berger A; Agrawal M (Journal of affective disorders, 2023)

Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment. - Meir P; Taylor L; Soares JC; Meyer TD (Journal of affective disorders, 2023)

The History, Legalization and Potentials of Psilocybin-Assisted Psychotherapy - Jeffery Heilman (Journal of Scientific Exploration, 2023)

Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. - Jones G; Lipson J; Wang E (Scientific reports, 2023)

The therapeutic potential of psychedelics: the European regulatory perspective - Florence Butlen-Ducuing; Drummond E-Wen McCulloch; Marion Haberkamp; Taina Mattila; Ewa Bałkowiec-Iskra; Georgios Aislaitner; П. В. Балабанов; Johan Lundberg; Dea Siggaard Stenbæk; André Elferink; Gitte M. Knudsen; Steffen Thirstrup (The Lancet, 2023)

Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines. - Henríquez-Hernández LA; Rojas-Hernández J; Quintana-Hernández DJ; Borkel LF (Toxics, 2023)

Wirkt Psilocybin nachhaltig antidepressiv? - Lea J. Mertens (InFo Neurologie + Psychiatrie, 2023)

More on psilocybin - Aryan Sarparast (Current Psychiatry, 2023)

Novel antidepressant drugs: Beyond monoamine targets. - Gonda X; Dome P; Neill JC; Tarazi FI (CNS spectrums, 2023)

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. - Ko K; Kopra EI; Cleare AJ; Rucker JJ (Journal of affective disorders, 2023)

Matrix-assisted laser-desorption/ionization-mass spectrometric imaging of psilocybin and its analogues in psychedelic mushrooms using a cesium chloride-coated target plate. - Wang H; Wang Y (Analytical and bioanalytical chemistry, 2023)

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation. - Burmester DR; Madsen MK; Szabo A; Aripaka SS; Stenbæk DS; Frokjaer VG; Elfving B; Mikkelsen JD; Knudsen GM; Fisher PM (Comprehensive psychoneuroendocrinology, 2023)

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines. - Cameron LP; Patel SD; Vargas MV; Barragan EV; Saeger HN; Warren HT; Chow WL; Gray JA; Olson DE (ACS chemical neuroscience, 2023)

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. - von Rotz R; Schindowski EM; Jungwirth J; Schuldt A; Rieser NM; Zahoranszky K; Seifritz E; Nowak A; Nowak P; Jäncke L; Preller KH; Vollenweider FX (EClinicalMedicine, 2023)

Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'. - von Rotz R; Schindowski EM; Jungwirth J; Schuldt A; Rieser NM; Zahoranszky K; Seifritz E; Nowak A; Nowak P; Jäncke L; Preller KH; Vollenweider FX (EClinicalMedicine, 2023)

Psilocybin therapy for depression. A good trip? - Rucker JJ (Journal of mental health (Abingdon, England), 2023)

Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health - Jennings Hernandez (Advances in Research, 2023)

SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression - Washington University School of Medicine (ClinicalTrials.gov, 2023)

Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective. - Stokłosa I; Więckiewicz G; Stokłosa M; Piegza M; Pudlo R; Gorczyca P (International journal of environmental research and public health, 2023)

Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial - Benjamin R. Lewis; Kevin Byrne; John Hendrick; Eric L. Garland; Paul Thielking; Anna C. Beck (Journal of Psychedelic Studies, 2023)

Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder - Dragana Marković; Eleonora Čapelja (AIDASCO Reviews, 2023)

Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder - Keith Heinzerling (ClinicalTrials.gov, 2023)

Is psilocybin an effective antidepressant and what is its Mechanism of action? - Mann JJ (Cell reports. Medicine, 2023)

Recruitment discrimination of lifetime classic psychedelic users is unjustified: Evidence from employees' motivation-based workplace absenteeism - Benjamin A. Korman (Journal of Psychedelic Studies, 2023)

Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands - Anna Lutkajtis; Jules Evans (Journal of Psychedelic Studies, 2023)

On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. - Gukasyan N (Med (New York, N.Y.), 2023)

Indigenous-Amazonian Traditional Medicine's Usage of the Tobacco Plant: A Transdisciplinary Ethnopsychological Mixed-Methods Case Study. - Berlowitz I; García Torres E; Maake C; Wolf U; Martin-Soelch C (Plants (Basel, Switzerland), 2023)

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. - Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; et al. (International journal of molecular sciences, 2023)

Conformational Landscape and Hydrogen Bonding Pattern of Psilocin: Computational Insights - Bhadoria Poonam; Ramanathan Venkatnarayan (ChemistrySelect, 2023)

Acute psilocybin enhances cognitive flexibility in rats. - Torrado Pacheco A; Olson RJ; Garza G; Moghaddam B (bioRxiv: the preprint server for biology, 2023)

Healing at death’s door: one patient’s mystical experience with psilocybin - Houman Farzin (International Journal of Whole Person Care, 2023)

The Therapeutic Potential of Psilocybin in Alcohol Use Disorder Recovery: A Literature Review - Kaden Venugopal; Nefissa Bedri (Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, 2023)

Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst - Andersen S. (PsyArXiv, 2023)

Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst - Sidsel Andersen (PsyArXiv, 2023)

Cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in South Africa - Sebastian William Foster (South African Journal on Human Rights, 2023)

Psilocybin in the treatment of generalized anxiety disorder (GAD), alcoholism and smoking: a literature review - Fabiano F. da Silva; Thaysa Adriane Costa Bernardo; Johny Ricarte das Silva Rodrigues; Pierre Teodósio Félix (IJS - International Journal of Sciences, 2023)

Psilocin esters - An investigation of synthetic feasibility, chemical, and metabolic stability - Eklund; Julia (Zenodo (CERN European Organization for Nuclear Research), 2023)

In Search of: A Federal Safe Harbor for State Legalization of Psilocybin - Tucker; Kathryn L.; Martinez; Holly; Morris; Ebony (Lewis & Clark Law Review, 2023)

Acute neurovascular effects of psilocybin administration in healthy humans: Implications for cerebral blood flow measurements using arterial spin labelling - Klaus Richter Larsen; Ulrich Lindberg; Brice Ozenne; Drummond E-Wen McCulloch; Sophia Armand; M. Madsen; Annette Johansen; Dea Siggaard Stenbæk; Gitte M. Knudsen; Patrick M. Fisher (Neuroscience Applied, 2023)

Psilocybin rescues depressive phenotype and modulates serotonin-2A and glucocorticoid receptor mRNA expression in brain cortex of a stress animal model - Ines Erkizia-Santamaría; Guadalupe Rivero; Igor Horrillo; J. Javier Meana; Jorge E. Ortega (Neuroscience Applied, 2023)

The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a long-term observational follow-up study - Guy M. Goodwin; Lindsey Marwood; S. Mistry; Anna Nowakowska; Zainib Shabir; H. Clifton Simmons; E.K. Teoh; Jeng-Yu Tsai; E. Malievskaia (Neuroscience Applied, 2023)

Effect of co-administration of low doses of psilocybin and mGluR2/3 antagonist LY341495 in chronic restraint stress model of depression - Agata Machaczka; Jane Turek; Dorota Bederska-Łojewska; Bartłomiej Pochwat; Łukasz Gąsior; Bernadeta Szewczyk; Andrzej Pilc (Neuroscience Applied, 2023)

Behavioral effects of a 14-day repeated treatment with psilocybin at a low non-psychedelic dose: a preliminary study in C57BL/6J mice - Sofia Nasini; Martina Colognesi; Sara Tidei; Sara De Martin; Marco Banzato; Andrea Mattarei; Franco Folli; P. Marco; Paolo L. Manfredi; Stefano Comai (Neuroscience Applied, 2023)

Withdrawal of antidepressants does not impact the efficacy of COMP360 psilocybin therapy: results from a phase IIb randomised controlled trial - Guy M. Goodwin; Megan Croal; J. Chai-Rees; Lindsey Marwood; S. Mistry; Anna Nowakowska; H. Clifton Simmons; Jeng-Yu Tsai (Neuroscience Applied, 2023)

Change in whole blood BDNF after escitalopram or psilocybin intervention in patients with depression and healthy controls - Miriam L. Navarro; Alberte Wollesen Breum; Annette Johansen; Brice Ozenne; Vibe G. Frøkjær; Gitte M. Knudsen (Neuroscience Applied, 2023)

A multi-metric evaluation of psilocybin effects on functional brain entropy in healthy volunteers - Drummond E-Wen McCulloch; Anders Smærup Olsen; Dea Siggaard Stenbæk; Sophia Armand; M. Madsen; Gitte M. Knudsen; Patrick M. Fisher (Neuroscience Applied, 2023)

Investigating changes in EEG entropy rate in response to psilocybin - a comparison of lempel ziv and state-space entropy rate measures - M. Nikolič; P. Mediano; Tom Froese; Tomáš Páleníček (Neuroscience Applied, 2023)

Visualizing drug actions on dendrites: psilocybin and other classic psychedelics - Shao Ling-Xiao; Liao Clara; Gregg Ian; Davoudian Pasha A; Savalia Neil K; Delagarza Kristina; Kwan Alex C. (Biophotonics Congress: Optics in the Life Sciences 2023 (OMA, NTM, BODA, OMP, BRAIN), 2023)

Italian psychedelic therapies of the past century: An historical overview - Adriana D’Arienzo; Giorgio Samorini (Drug Science Policy and Law, 2023)

Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data - Peter Hess (The Transmitter, 2023)

Company on brink takes psilocybin to trial for fragile X syndrome - Peter Hess (The Transmitter, 2023)

Therapeutic mechanism of psilocybin in the treatment of depression and other psychiatric disorders. - O. Shahar; A. Botvinik; T. Lifschytz; B. Lerer (Neuroscience Applied, 2023)

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses - Peter Hess (The Transmitter, 2023)

Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change - Nadiia Omelchenko; Anton Kurapov (Bulletin of Taras Shevchenko National University of Kyiv Psychology, 2023)

Psychedelic Drug Therapy for Mental Disorders? - John R. Rossiter (Open Journal of Medical Psychology, 2023)

The right to privacy in the decriminalisation of psilocybin mushrooms in South Africa - Sebastian William Foster (Law Democracy & Development, 2023)

Psilocybin as a treatment for anorexia nervosa: 6-week and 3-month follow-up results - Hannah Douglass; Merle Spriggs; Kate Godfrey; Jennifer L. Danby; Francisco Magalhães; Kirsty L. Alderton; Liane Macdonald; Stephanie Archer; Tim Read; Adèle Lafrance; Dasha Nicholls; David Erritzøe; et al. (Neuroscience Applied, 2023)

A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness - Jaden Brandt (Drug Science Policy and Law, 2023)

Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use - Brian S. Barnett; Noah Wiles Sweat; Peter S. Hendricks (Drug Science Policy and Law, 2023)

Predictors of Psychedelic Experience: A Thematic Analysis. - McCartney AM; McGovern HT; De Foe A (Journal of psychoactive drugs, 2023)

Electrophysiological study of visual and auditory processing in psilocin-induced hallucinations: exploring evoked potentials and 5-HT2A receptor involvement - Vejmola Č.; Hubený J.; Koudelka V.; Griškova-Bulanova I.; Páleníček T. (Neuroscience Applied, 2023)

Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States. - Simonsson O; Goldberg SB (Journal of psychoactive drugs, 2023)

The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. - Hadar A; David J; Shalit N; Roseman L; Gross R; Sessa B; Lev-Ran S (Journal of psychoactive drugs, 2023)

Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. - Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF (Journal of psychoactive drugs, 2023)

The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. - Hodge AT; Sukpraprut-Braaten S; Narlesky M; Strayhan RC (Journal of psychoactive drugs, 2023)

How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression? - Earleywine M; Low F; Altman BR; De Leo J (Journal of psychoactive drugs, 2023)

Sustained effects of single doses of classical psychedelics in humans. - Knudsen GM (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2023)

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. - Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; et al. (Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2023)

Towards an understanding of psychedelic-induced neuroplasticity. - Calder AE; Hasler G (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2023)

The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. - Johnston CB; Mangini M; Grob C; Anderson B (The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry, 2023)

Mescaline: The forgotten psychedelic. - Vamvakopoulou IA; Narine KAD; Campbell I; Dyck JRB; Nutt DJ (Neuropharmacology, 2023)

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. - Jones GM (Journal of psychopharmacology (Oxford, England), 2023)

Psilocin - The “real deal” or an extraction byproduct - Gutman Ori; Tenne Dana; Bretler Uriel (Journal of Forensic Sciences, 2023)

Body mass index (BMI) does not predict responses to psilocybin. - Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL (Journal of psychopharmacology (Oxford, England), 2023)

Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. - Kious B; Schwartz Z; Lewis B (Journal of psychopharmacology (Oxford, England), 2023)

Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. - Shukuroglou M; Roseman L; Wall M; Nutt D; Kaelen M; Carhart-Harris R (Journal of psychopharmacology (Oxford, England), 2023)

Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome. - Buzzelli V; Carbone E; Manduca A; Schiavi S; Feo A; Perederiy JV; Ambert KH; Hausman M; Trezza V (Psychopharmacology, 2023)

Psychedelic Drug Legislative Reform and Legalization in the US. - Siegel JS; Daily JE; Perry DA; Nicol GE (JAMA psychiatry, 2023)

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. - Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J (Journal of psychopharmacology (Oxford, England), 2023)

Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. - Meccia J; Lopez J; Bagot RC (Psychopharmacology, 2023)

Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. - Henningfield JE; Ashworth J; Heal DJ; Smith SL (Journal of psychopharmacology (Oxford, England), 2023)

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. - Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D (Journal of psychopharmacology (Oxford, England), 2023)

Psilocybin in Palliative Care: An Update. - Whinkin E; Opalka M; Watters C; Jaffe A; Aggarwal S (Current geriatrics reports, 2023)

Functional MRI markers for treatment-resistant depression: Insights and challenges. - Kotoula V; Evans JW; Punturieri C; Johnson SC; Zarate CA (Progress in brain research, 2023)

Next generation antidepressants with novel mechanisms for treatment resistant depression. - Chen MH; Tu PC; Su TP (Progress in brain research, 2023)

The Resurgence of Hallucinogen Drugs in Clinical Research. - Rivera-García MT; Cruz SL (Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 2023)

Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response. - Unzueta-Larrinaga P; Urigüen L (Methods in molecular biology (Clifton, N.J.), 2023)

Biological embedding of early trauma: the role of higher prefrontal synaptic strength. - Tamman AJF; Jiang L; Averill CL; Mason GF; Averill LA; Abdallah CG (European journal of psychotraumatology, 2023)

UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES. - Ahmed H; Mushahid H; Arshad T (Psychiatria Danubina, 2023)

Efficacy and Safety of Psychedelics in Treating Anxiety Disorders. - Feulner L; Sermchaiwong T; Rodland N; Galarneau D (Ochsner journal, 2023)

Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. - Edelsohn GA; Sisti D (Perspectives in biology and medicine, 2023)

When art therapy went chemical: Alfred Bader, pharmacology, and art brut, c.1950-1970s. - Martinovic J (Historia, ciencias, saude–Manguinhos, 2023)

Classic psychedelics do not affect T cell and monocyte immune responses. - Rudin D; Areesanan A; Liechti ME; Gründemann C (Frontiers in psychiatry, 2023)

Therapeutic effect of psilocybin in addiction: A systematic review. - van der Meer PB; Fuentes JJ; Kaptein AA; Schoones JW; de Waal MM; Goudriaan AE; Kramers K; Schellekens A; Somers M; Bossong MG; Batalla A (Frontiers in psychiatry, 2023)

Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report. - Ragnhildstveit A; Kaiyo M; Snyder MB; Jackson LK; Lopez A; Mayo C; Miranda AC; August RJ; Seli P; Robison R; Averill LA (Frontiers in psychiatry, 2023)

Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBG. - Chen Y; Liu J; Yao Y; Yan H; Su R (Frontiers in pharmacology, 2023)

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. - Kinderlehrer DA (International medical case reports journal, 2023)

Editorial: What is up with psychedelics anyway? - Lewis CR; McMurray M; Mennenga SE; Helms Tillery S (Frontiers in neuroscience, 2023)

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. - Brett J; Knock E; Korthuis PT; Liknaitzky P; Murnane KS; Nicholas CR; Patterson JC; Stauffer CS (Frontiers in psychiatry, 2023)

Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders. - Vorobyeva N; Kozlova AA (Frontiers in pharmacology, 2023)

Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences. - Shaw L; Rea K; Lachowsky NJ; Roth EA (Journal of psychoactive drugs, 2023)

Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users. - Fauvel B; Kangaslampi S; Strika-Bruneau L; Roméo B; Piolino P (Journal of psychoactive drugs, 2023)

Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. - Kelly JR; Clarke G; Harkin A; Corr SC; Galvin S; Pradeep V; Cryan JF; O'Keane V; Dinan TG (International journal of clinical and health psychology: IJCHP, 2023)

The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials. - IsHak WW; Garcia P; Pearl R; Dang J; William C; Totlani J; Danovitch I (Innovations in clinical neuroscience, 2023)

Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives. - Rankaduwa S; Owen AM (Neuroscience of consciousness, 2023)

Use of Selective Alternative Therapies for Treatment of OCD. - Khan I; Jaura TA; Tukruna A; Arif A; Tebha SS; Nasir S; Mukherjee D; Masroor N; Yosufi A (Neuropsychiatric disease and treatment, 2023)

Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique. - Mosurinjohn S; Roseman L; Girn M (Frontiers in psychiatry, 2023)

Mini-review: The neurobiology of treating substance use disorders with classical psychedelics. - Urban MM; Stingl MR; Meinhardt MW (Frontiers in neuroscience, 2023)

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. - Ching THW; Grazioplene R; Bohner C; Kichuk SA; DePalmer G; D'Amico E; Eilbott J; Jankovsky A; Burke M; Hokanson J; Martins B; Witherow C; et al. (Frontiers in psychiatry, 2023)

Empirically validated theoretical analysis of visual-spatial perception under change of nervous system arousal. - Purohit P; Dutta P; Roy PK (Frontiers in computational neuroscience, 2023)

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders. - Blest-Hopley G; Amit BH; O'Neill A; Ruffell SGD (Frontiers in psychiatry, 2023)

Henri Michaux's program for the psychedelic humanities. - Davis O (Frontiers in psychology, 2023)

Acute psilocybin increased cortical activities in rats. - Liu J; Wang Y; Xia K; Wu J; Zheng D; Cai A; Yan H; Su R (Frontiers in neuroscience, 2023)

The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics. - Evens R; Schmidt ME; Majić T; Schmidt TT (Therapeutic advances in psychopharmacology, 2023)

A case-study evaluation of the "Copenhagen Music Program" for psilocybin-assisted therapy. - Ratkovic G; Sosteric M; Sosteric T (Frontiers in psychology, 2023)

Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder. - Phan AN; Terry GE (Frontiers in psychiatry, 2023)

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review. - Zhornitsky S; Oliva HNP; Jayne LA; Allsop ASA; Kaye AP; Potenza MN; Angarita GA (Frontiers in psychiatry, 2023)

Medical student attitudes and perceptions of psychedelic-assisted therapies. - Li I; Fong R; Hagen M; Tabaac B (Frontiers in psychiatry, 2023)

Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. - Blond BN; Schindler EAD (Frontiers in neurology, 2023)

Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective. - De La Haye W; Walcott G; Eaton J; Beckford J; Greene J (Frontiers in psychiatry, 2023)

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study. - Hartong V; van Emmerik A (Journal of psychoactive drugs, 2023)

What is the progress of experimental drug development for fibromyalgia? - Lawson K (Expert opinion on investigational drugs, 2023)

Serotonin 5-HT receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. - McIntyre RS (Expert opinion on drug safety, 2023)

Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents. - McIntyre RS (Expert opinion on drug safety, 2023)

Adapting psychedelic medicine for headache and chronic pain disorders. - Schindler EAD; Hendricks PS (Expert review of neurotherapeutics, 2023)

Assessing potential of psilocybin for depressive disorders. - Kozak Z; Johnson MW; Aaronson ST (Expert opinion on investigational drugs, 2023)

Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development. - Simonsson O; Stenfors CUD; Goldberg SB; Hendricks PS; Osika W (Frontiers in psychology, 2023)

Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study. - Więckiewicz G; Stokłosa I; Stokłosa M; Więckiewicz W; Gorczyca P; Gondek TM (Frontiers in psychiatry, 2023)

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. - Boehnke KF; Cox K; Weston C; Herberholz M; Glynos N; Kolbman N; Fields CW; Barron J; Kruger DJ (Frontiers in psychiatry, 2023)

Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics. - Abrams SK; Rabinovitch BS; Zafar R; Aziz AS; Cherup NP; McMillan DW; Nielson JL; Lewis EC (Neurotrauma reports, 2023)

Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests. - Jones G; Al-Suwaidi M; Castro-Ramirez F; McGuire TC; Mair P; Nock MK (Frontiers in psychiatry, 2023)

The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness. - Longo MSC; Bienemann B; Multedo M; Negreiros MA; Schenberg E; Mograbi DC (Journal of psychoactive drugs, 2023)

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials. - Herrmann Z; Earleywine M; De Leo J; Slabaugh S; Kenny T; Rush AJ (Journal of psychoactive drugs, 2023)

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. - Weleff J; Akiki TJ; Barnett BS (Journal of psychoactive drugs, 2023)

An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically. - Kruger DJ; Glynos NG; Fields CW; Herberholz M; Boehnke KF (Journal of psychoactive drugs, 2023)

History of the administration of psychedelics in France. - Dubus Z; Grandgeorge E; Verroust V (Frontiers in psychology, 2023)

Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report. - Lawrence DW (Innovations in clinical neuroscience, 2023)

Psychedelics for treatment resistant depression: are they game changers? - Kalfas M; Taylor RH; Tsapekos D; Young AH (Expert opinion on pharmacotherapy, 2023)

Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. - Heinzerling KG; Sergi K; Linton M; Rich R; Youssef B; Bentancourt I; Bramen J; Siddarth P; Schwartzberg L; Kelly DF (Frontiers in psychiatry, 2023)

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. - Nayak SM; Jackson H; Sepeda ND; Mathai DS; So S; Yaffe A; Zaki H; Brasher TJ; Lowe MX; Jolly DRP; Barrett FS; Griffiths RR; et al. (Frontiers in psychiatry, 2023)

Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the "high-risk" addiction patient. - Black T (Frontiers in psychiatry, 2023)

Manic episode following psilocybin use in a man with bipolar II disorder: a case report. - Halim HJ; Burk BG; Fargason RE; Birur B (Frontiers in psychiatry, 2023)

Bedside to bench: the outlook for psychedelic research. - Acero VP; Cribas ES; Browne KD; Rivellini O; Burrell JC; O'Donnell JC; Das S; Cullen DK (Frontiers in pharmacology, 2023)

Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis. - Ko K; Carter B; Cleare AJ; Rucker JJ (Neuropsychiatric disease and treatment, 2023)

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges. - Barnett BS; Bassir Nia A; Sackett NB; Weleff J (Frontiers in psychiatry, 2023)

Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. - Sharma R; Batchelor R; Sin J (Journal of psychoactive drugs, 2023)

"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics. - Kruger DJ; Enghoff O; Herberholz M; Barron J; Boehnke KF (Journal of psychoactive drugs, 2023)

A Proposal to Study the Safety and Efficacy of in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder. - Escamilla R; González-Trujano ME; González Mariscal JM; Torres-Valencia JM; Guzmán-González H; Vega JL; Loizaga-Velder A (Journal of psychoactive drugs, 2023)

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. - Kovacevich A; Weleff J; Claytor B; Barnett BS (Journal of psychoactive drugs, 2023)

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. - Kvam TM; Uthaug MV; Andersen KAA; Refsum BB; Tunstad PA; Stewart LH; Jacobsen HB; Grønnerød C (Frontiers in psychiatry, 2023)

Biological studies of clavine alkaloids targeting CNS receptors. - Tasker NR; Pazur EJ; Wipf P (Frontiers in psychiatry, 2023)

Exploring spp. mycelium and fruiting body chemistry for potential therapeutic compounds. - Waldbillig A; Baranova M; Neumann S; Andrade J; Sidhu S (Frontiers in fungal biology, 2023)

Group psychedelic therapy: empirical estimates of cost-savings and improved access. - Marseille E; Stauffer CS; Agrawal M; Thambi P; Roddy K; Mithoefer M; Bertozzi SM; Kahn JG (Frontiers in psychiatry, 2023)

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. - Ching THW; Amoroso L; Bohner C; D'Amico E; Eilbott J; Entezar T; Fitzpatrick M; Fram G; Grazioplene R; Hokanson J; Kichuk SA; Martins B; et al. (Frontiers in psychiatry, 2023)

Psychedelics, epilepsy, and seizures: a review. - Freidel N; Kreuder L; Rabinovitch BS; Chen FY; Huang RST; Lewis EC (Frontiers in pharmacology, 2023)

Ego Birth: Measure 109, The NMHA, and Forward Movement in the Nascent Psilocybin Industry - Andrew M. Robie (SSRN Electronic Journal, 2022)

From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia - Octavian Dixon Ritchie; Cameron N Donley; Gabrielle Dixon Ritchie (Drug Science Policy and Law, 2022)

Psilocybin for Depression: From Credibility to Feasibility, What's Missing? - Munafò A; Arillotta D; Mannaioni G; Schifano F; Bernardini R; Cantarella G (Pharmaceuticals (Basel, Switzerland), 2022)

The Potential of Psilocybe Genus Fungi to Treat Depression and Some Addictions - Vanessa Eveline VLAIC; Andreea ONA (Hop and Medicinal Plants, 2022)

A Review of Synthetic Access to Therapeutic Compounds Extracted from. - Serreau R; Amirouche A; Benyamina A; Berteina-Raboin S (Pharmaceuticals (Basel, Switzerland), 2022)

Depression Improves Following Single Dose of Psilocybin - Nick Zagorski (Psychiatric News, 2022)

DNA Authentication and Chemical Analysis of Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites. - Bradshaw AJ; Backman TA; Ramírez-Cruz V; Forrister DL; Winter JM; Guzmán-Dávalos L; Furci G; Stamets P; Dentinger BTM (Applied and environmental microbiology, 2022)

Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents. - Jones G; Arias D; Nock M (Scientific reports, 2022)

High time? Psychedelics on cannabis-like fast track to legalization - Kevin Zannese (Canadian Medical Association Journal, 2022)

Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis. - Schäfer T; Kramer K; Werten S; Rupp B; Hoffmeister D (Chembiochem: a European journal of chemical biology, 2022)

Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster - Bradshaw AJ; Ramírez-Cruz V; Awan AR; Furci G; Guzmán-Dávalos L; Stamets P; Dentinger BT. (bioRxiv, 2022)

Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum - Geoffrey M. Bove; David J. Mokler (Journal of Psychedelic Studies, 2022)

Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice. - Pędzich BD; Medrano M; Buckinx A; Smolders I; De Bundel D (International journal of molecular sciences, 2022)

Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens - Magiatis P; Dadiotis E; Antonopoulos R K; Ioannidis K; Mitsis V; Melliou E; Gonou-Zagou Z (Planta Medica, 2022)

The psychedelic renaissance: the next trip for psychiatry? - Kelly JR; Baker A; Babiker M; Burke L; Brennan C; O'Keane V (Irish journal of psychological medicine, 2022)

Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019. - Walsh CA; Livne O; Shmulewitz D; Stohl M; Hasin DS (Addictive behaviors reports, 2022)

Set and setting in microdosing: an oft-overlooked principle. - Hartogsohn I; Petranker R (Psychopharmacology, 2022)

Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. - O'Donnell KC; Mennenga SE; Owens LT; Podrebarac SK; Baron T; Rotrosen J; Ross S; Forcehimes AA; Bogenschutz MP (Contemporary clinical trials, 2022)

Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. - Strauss D; Ghosh S; Murray Z; Gryzenhout M (3 Biotech, 2022)

Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects - Olsen Anders S.; Lykkebo-Valløe Anders; Ozenne Brice; Madsen Martin K.; Stenbæk Dea S.; Armand Sophia; Mørup Morten; Ganz Melanie; Knudsen Gitte M.; Fisher Patrick M. (NeuroImage, 2022)

Psychedelic-Assisted Therapy for People with Eating Disorders. - Gukasyan N; Schreyer CC; Griffiths RR; Guarda AS (Current psychiatry reports, 2022)

A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. - Barber G; Nemeroff CB; Siegel S (The American journal of psychiatry, 2022)

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. - Kelmendi B; Kichuk SA; DePalmer G; Maloney G; Ching THW; Belser A; Pittenger C (Heliyon, 2022)

Antidepressant properties of psilocybin might be related to changes in sleep - Dooper Marten (Medicom Conference Report ECNP 2022, 2022)

Fast and sustained effect of 2 administrations of psilocybin on depression - Dooper Marten (Medicom Conference Report ECNP 2022, 2022)

Mode of action of psilocybin - Dooper Marten (Medicom Conference Report ECNP 2022, 2022)

NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System. - NWTraumatherapies (ClinicalTrials.gov, 2022)

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications. - Shahar O; Botvinnik A; Esh-Zuntz N; Brownstien M; Wolf R; Lotan A; Wolf G; Lerer B; Lifschytz T (International journal of molecular sciences, 2022)

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine - Guss J; Krause R; Sloshower J. (PsyArXiv, 2022)

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine - Jeffrey Guss; Robert Krause; Jordan Sloshower (PsyArXiv, 2022)

Psychedelic compounds directly excite 5-HT2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT2A Gq -mediated activation mechanism - Schmitz GP; Chiu Y; König GM; Kostenis E; Roth BL; Herman MA. (bioRxiv, 2022)

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. - Belouin SJ; Averill LA; Henningfield JE; Xenakis SN; Donato I; Grob CS; Berger A; Magar V; Danforth AL; Anderson BT (Neuropharmacology, 2022)

Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids. - Gotvaldová K; Borovička J; Hájková K; Cihlářová P; Rockefeller A; Kuchař M (International journal of molecular sciences, 2022)

Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice. - Glatfelter GC; Pottie E; Partilla JS; Sherwood AM; Kaylo K; Pham DNK; Naeem M; Sammeta VR; DeBoer S; Golen JA; Hulley EB; Stove CP; et al. (ACS pharmacology & translational science, 2022)

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence - NYU Langone Health (ClinicalTrials.gov, 2022)

Experts assess role of therapists in psychedelic-assisted therapy - Valerie A. Canady (Mental Health Weekly, 2022)

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice - Jefferson SJ; Gregg I; Dibbs M; Liao C; Wu H; Davoudian PA; Sprouse JS; Sherwood AM; Kaye AP; Pittenger C; Kwan AC. (bioRxiv, 2022)

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. - Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; et al. (The New England journal of medicine, 2022)

Psilocybin in Treatment-Resistant Depression. - Madras BK (The New England journal of medicine, 2022)

Psilocybin reduces symptoms in treatment resistant depression, trial results show. - Iacobucci G (BMJ (Clinical research ed.), 2022)

The psychedelic renaissance: can psilocybin possibly combat depression? - Hamna Raheel; Unaiza Naeem; Asim Shaikh; Omer Ahmed Shaikh (International Journal of Surgery Global Health, 2022)

Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers - Mason N; Szabo A; Kuypers K; Mallaroni P; de la Torre Fornell R; Reckweg J; Tse D; Hutten N; Feilding A; Ramaekers J. (medRxiv, 2022)